FLT3 inhibitors in acute myeloid leukemia

Table 2 Clinical trials of sorafenib in hematopoietic stem cell transplantation

Study agents	Other agents	Disease	No Pts	Response	Reference
Sorafenib	Allo-HSCT		17	CR 82%	[22]
Sorafenib	Allo-HSCT		144	3-year OS 74.9%/78.1%/84.6%/50.9% 3-year relapse rates 22.2%/18.8%/15.8%/46.1% 3-year LFS rates 69.4%/78.1%/80.4%/ 34.8%	[23]
Sorafenib	Maintenance		81	2-year OS 81% 2-year PFS 82% 2-year relapse incidence 8.2%	[24]
Sorafenib	Maintenance		27	1-year OS 92 ± 6% 1-year PFS 92 ± 5%	[25]
Sorafenib	Chemotherapy Monotherapy	Relapsed	16	CR 81%	[26]

CR complete remission, OS overall survival, PFS progression-free survival, allo-HSCT allogeneic hematopoietic stem cell transplantation, LFS leukemia-free survival

ISSN: 1756-8722